ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

 

Oral Presentation:

 

Title: Rational Design of a Vaccine for Alzheimer’s Disease Using Computationally-Derived Conformational B Cell Epitopes to Selectively Target Toxic Amyloid-Beta Oligomers

 

Session: S26: Experimental Therapeutics in Dementia (abstract #4532)

 

Presenter: Dr. Johanne Kaplan

 

Date & Time: April 25, 2023 at 1:36 p.m. ET

 

Poster Presentations:

 

Title: Protection Against Toxic Amyloid-Beta Oligomers by PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency in Alzheimer’s Disease

 

Session: P1: Aging and Dementia: Basic Science (abstract #4597)

 

Presenter: Dr. Johanne Kaplan

 

Date & Time: April 23, 2023 from 8:00 – 9:00 a.m. ET

 

Title: RACK1 Knockdown Is a Potential Therapeutic Target in ALS and FTLD-TDP

 

Session: P1: Aging and Dementia: Basic Science (abstract #3494)

 

Presenter: Dr. Neil Cashman

 

Date & Time: April 23, 2023 from 8:00 – 9:00 a.m. ET

 

About ProMIS Neurosciences Inc.

 

ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform – ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.

 

For further information:

 

Visit us at www.promisneurosciences.com

Please submit media inquiries to info@promisneurosciences.com

 

For Investor Relations, please contact:

 

Stern Investor Relations

Suzanne Messere, Managing Director

suzanne.messere@sternir.com

Tel. 212 698-8801